Bladder Cancer Coverage from Every Angle

Massimo Di Maio, MD, on Niraparib and Best Supportive Care as Maintenance Therapy for Urothelial Cancer

Posted: Thursday, March 31, 2022

Massimo Di Maio, MD, of the University of Turin, discusses findings of the Meet-URO12 trial, which showed that maintenance niraparib plus best supportive care (BSC) did not prolong progression-free survival, compared with BSC alone, among patients with urothelial cancer that did not progress after first-line platinum-based chemotherapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.